A new analysis from the Office of Inspector General found a similar net cost for drugs through vertically-integrated Part D plans compared to other plans. | A new analysis from the Office of Inspector General found a similar net cost for drugs through vertically-integrated Part D plans compared to other plans.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Sixty-seven percent of healthcare system leaders are “very or extremely” concerned about Medicaid and Medicare reimbursement…
Strengthening core CDO values for cell line development | Strengthening core CDO values for cell line development
Nearly 80% of payers now prefer implementing vendor-built artificial intelligence tools rather than developing internal…
There’s a thing that happens in American healthcare.You've got these massive systems—pharma conglomerates, hospital networks,…
With questions already swirling about the actual affordability impact of t | With questions already swirling about the actual…
A new ad campaign takes aim at the "misaligned incentives" in the No Surprises Act arbitration process, arguing they "create a…
The Case for Direct-to-Patient Is Clear, The Challenge Now is Successful Execution
